Kamada Ltd. Reports Strong Q3 2026 Results and Raises Full-Year Guidance
Kamada Ltd. (KMDA) reported robust third-quarter 2026 financial results, highlighted by an 11% year-over-year increase in total revenue to $52 million. The company saw significant growth in net income, which rose 51% to $8 million, and adjusted EBITDA, which climbed 30% to $15.2 million. This performance was primarily driven by the strong utilization of KEDRAB and expansion within its distribution segment. Following these results, management raised its full-year 2026 revenue guidance to a range of $205 million to $208 million. The company is also executing a vertical integration strategy through new plasma supply agreements and the operation of FDA-approved collection centers in Texas. Looking ahead, Kamada projects double-digit growth for both revenues and profitability in 2027, supported by an expanding biosimilar pipeline.
Topics: Biosimilars EBITDA Financial Guidance Market Share Revenue Growth